CJC-1295 with DAC is a modified growth hormone-releasing hormone analog (tetrasubstituted GRF 1-29) conjugated to Drug Affinity Complex (DAC) via a lysine linker. CAS 863288-34-0, molecular weight ~3647 Da. The DAC moiety enables albumin binding, extending plasma half-life to approximately 6-8 days in research models. Compuesto solo para investigación de laboratorio.
Especificaciones del compuesto
CJC-1295 with DAC is a modified GHRH(1-29) analog conjugated to a Drug Affinity Complex (maleimidopropionic acid–lysine linker) that enables covalent binding to serum albumin. The base peptide has CAS 863288-34-0. The DAC modification extends the half-life to approximately 6–8 days by preventing renal clearance. Molecular weight approximately 3647 Da (peptide + linker). Compuesto solo para investigación de laboratorio.
Detalles del producto
- Compuesto: CJC-1295 with DAC (Drug Affinity Complex)
- Pureza: >99%
- Forma: Polvo liofilizado
- Pruebas: Ver COA (Verificado por Janoshik) →
mg
📚 Ver investigación publicada sobre CJC-1295 with DAC →
Citas revisadas por pares de PubMed, solo con fines educativos
CJC-1295 with DAC documentation path
This CJC-1295 with DAC listing is organized for analog identity, DAC albumin-binding context, and batch-documentation review. It is not intended to guide use or protocol design.
- Identidad: modified GHRH(1-29) analog with Drug Affinity Complex; base peptide CAS 863288-34-0.
- Documentation: review COA records y Calidad y pruebas.
- Literature context: see CJC-1295 with DAC research y CJC-1295 + Ipamorelin research.
Research use only. This page does not provide dosing, administration, reconstitution, treatment, hormone-use, or human-use guidance.